Clinical Trials Browser

Phase 1 × spartalizumab × Thoracic × Clear all

NCT03891953 2026-01-21

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Phase 1 Active not recruiting

98 enrolled

BreastDermatologicHead & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms

NCT07318636 2026-01-06

NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

Phase 1 Not yet recruiting

10 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Phase 1 Terminated

122 enrolled

GastrointestinalHead & NeckSarcomaThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT04261439 2025-05-06

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Phase 1 Terminated

60 enrolled

DermatologicLymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma

NCT03860272 2025-02-06

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Phase 1 Active not recruiting

499 enrolled

GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT03549000 2024-12-13

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Phase 1 Terminated

127 enrolled

BreastGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04672434 2024-12-09

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Phase 1 Completed

48 enrolled

GastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Phase 1 Completed

298 enrolled

BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03064854 2022-08-15

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Phase 1 Terminated

111 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1 Completed

283 enrolled

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT02947165 2022-01-31

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1 Completed

120 enrolled

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02403193 2022-01-12

AdenONCO

Phase 1 Completed

92 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung